{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:30:39Z","timestamp":1793946639507,"version":"4.8.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.eclinm.2026.104211","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:19:13Z","timestamp":1790165953000},"page":"104211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Tumour-agnostic immunotherapy: aligning biological rationale, biomarker precision, and real-world implementation"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4442-6516","authenticated-orcid":false,"given":"Jia","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8898-0549","authenticated-orcid":false,"given":"Juliana","family":"Beal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niamh","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lynam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Subbiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6349","key":"10.1016\/j.eclinm.2026.104211_bib1","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104211_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.eclinm.2026.104211_bib3","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMp1709968","article-title":"First FDA approval agnostic of cancer site - when a biomarker defines the indication","volume":"377","author":"Lemery","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104211_bib4","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/EDBK_173855","article-title":"Tissue-agnostic drug development","volume":"37","author":"Flaherty","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104211_bib5","first-page":"433","article-title":"The evolving landscape of tissue-agnostic therapies in precision oncology","volume":"74","author":"Subbiah","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104211_bib6","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104211_bib7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.eclinm.2026.104211_bib8","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1001\/jamaoncol.2019.2963","article-title":"Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.eclinm.2026.104211_bib9","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jamaoncol.2018.1701","article-title":"Prevalence of PDL1 amplification and preliminary response to immune checkpoint blockade in solid tumors","volume":"4","author":"Goodman","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eclinm.2026.104211_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2026.116784","article-title":"The case for tumour-agnostic reimbursement of dual immunotherapy","volume":"241","author":"Subbiah","year":"2026","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.eclinm.2026.104211_bib13","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41571-026-01167-6","article-title":"Realizing the benefits of tumour-agnostic access requires a national health learning system","volume":"23","author":"Stevens","year":"2026","journal-title":"Nat Rev Clin Oncol"},{"issue":"6439","key":"10.1016\/j.eclinm.2026.104211_bib14","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1126\/science.aau0447","article-title":"Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response","volume":"364","author":"Mandal","year":"2019","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104211_bib15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","article-title":"The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints","volume":"5","author":"Llosa","year":"2015","journal-title":"Cancer Discov"},{"issue":"11","key":"10.1016\/j.eclinm.2026.104211_bib16","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.41165","article-title":"Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: a nonrandomized controlled trial","volume":"6","author":"Andre","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.eclinm.2026.104211_bib17","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.eclinm.2026.104211_bib18","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"7793","key":"10.1016\/j.eclinm.2026.104211_bib19","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104211_bib20","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104211_bib21","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104211_bib22","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1038\/s41467-025-57941-0","article-title":"Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvals","volume":"16","author":"Sledge","year":"2025","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104211_bib23","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"6371","key":"10.1016\/j.eclinm.2026.104211_bib24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"issue":"6371","key":"10.1016\/j.eclinm.2026.104211_bib25","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"issue":"7804","key":"10.1016\/j.eclinm.2026.104211_bib26","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41586-020-2209-9","article-title":"Mechanisms and therapeutic implications of hypermutation in gliomas","volume":"580","author":"Touat","year":"2020","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.eclinm.2026.104211_bib27","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jtho.2018.05.013","article-title":"PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project","volume":"13","author":"Tsao","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"7","key":"10.1016\/j.eclinm.2026.104211_bib28","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/s41588-022-01108-w","article-title":"Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity","volume":"54","author":"Ma","year":"2022","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.eclinm.2026.104211_bib29","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","article-title":"Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer","volume":"24","author":"Kim","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.eclinm.2026.104211_bib54","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010130","article-title":"Evaluation of immune checkpoint inhibitor efficacy for solid tumors with CD274 (PD-L1 gene) amplification identified by comprehensive genomic profiling: retrospective study based on a nationwide database","volume":"12","author":"Nakayama","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"6411","key":"10.1016\/j.eclinm.2026.104211_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104211_bib33","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2026.104211_bib34","article-title":"Tumor-agnostic therapies: translating scientific breakthroughs into global implementation","author":"Liu","year":"2026","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.eclinm.2026.104211_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100290","article-title":"Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up","volume":"6","author":"D'Angelo","year":"2021","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.eclinm.2026.104211_bib31","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2303383","article-title":"Atezolizumab for advanced alveolar soft part sarcoma","volume":"389","author":"Chen","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.eclinm.2026.104211_bib35","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.annonc.2026.04.004","article-title":"Dart (NCI\/SWOG S1609): comprehensive final results from dual checkpoint inhibition with CTLA-4 and PD-1 blockade in rare cancers","volume":"37","author":"Patel","year":"2026","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.eclinm.2026.104211_bib36","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-19-3356","article-title":"A phase II basket trial of dual Anti-CTLA-4 and Anti-PD-1 blockade in rare tumors (DART SWOG 1609) in patients with nonpancreatic neuroendocrine tumors","volume":"26","author":"Patel","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.eclinm.2026.104211_bib37","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1002\/cncr.33591","article-title":"A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort","volume":"127","author":"Patel","year":"2021","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.eclinm.2026.104211_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002990","article-title":"Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)","volume":"9","author":"Wagner","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104211_bib39","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012805","article-title":"DART\/SWOG\/NCI phase II anti-CTLA-4\/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix","volume":"14","author":"Chae","year":"2026","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.eclinm.2026.104211_bib40","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaoncol.2025.1916","article-title":"Nivolumab and ipilimumab combination treatment in advanced ovarian and endometrial clear cell cancers: a nonrandomized clinical trial","volume":"11","author":"Gao","year":"2025","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104211_bib41","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/jamaoncol.2025.4721","article-title":"Nivolumab and ipilimumab in advanced mismatch repair-deficient\/microsatellite instability-high noncolorectal cancers: a nonrandomized clinical trial","volume":"12","author":"Carlino","year":"2026","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eclinm.2026.104211_bib42","series-title":"Guidelines for Preparing a Submission to the Pharmaceutical Benefits Advisory Committee Version 5.0","year":"2016"},{"key":"10.1016\/j.eclinm.2026.104211_bib43","series-title":"What we assess","year":"2024"},{"key":"10.1016\/j.eclinm.2026.104211_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2026.116785","article-title":"Bypassing the evidence pathway: World-first tumour-agnostic reimbursement for dual immunotherapy","volume":"241","author":"Barjesteh van Waalwijk van Doorn-Khosrovani","year":"2026","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eclinm.2026.104211_bib45","series-title":"Tumour-Agnostic Advanced or Metastatic Ipilimumab and\/or Nivolumab","year":"2026"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104211_bib46","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2217\/lmt-2016-0016","article-title":"Cost-effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression","volume":"5","author":"Aguiar","year":"2016","journal-title":"Lung Cancer Manag"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104211_bib47","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s40261-023-01254-x","article-title":"Spending, utilization, and price trends for immune checkpoint inhibitors in US medicaid programs: an empirical analysis from 2011 to 2021","volume":"43","author":"Shin","year":"2023","journal-title":"Clin Drug Investig"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104211_bib48","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s40425-018-0442-7","article-title":"A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors","volume":"6","author":"Verma","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104211_bib49","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000496834","article-title":"What does the pipeline promise about upcoming biosimilar antibodies in oncology?","volume":"14","author":"Busse","year":"2019","journal-title":"Breast Care"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104211_bib50","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41416-024-02887-1","article-title":"Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review","volume":"132","author":"Jayathilaka","year":"2025","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.eclinm.2026.104211_bib51","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104211_bib52","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1158\/1078-0432.CCR-25-3103","article-title":"Predictive biomarkers of antibody-drug conjugate efficacy for solid tumors: current challenges and the potential role of quantitative proteomics","volume":"32","author":"McNamee","year":"2026","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.eclinm.2026.104211_bib53","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","article-title":"The journey of antibody-drug conjugates: lessons learned from 40 years of development","volume":"14","author":"Colombo","year":"2024","journal-title":"Cancer Discov"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026004645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026004645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:51:54Z","timestamp":1793944314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026004645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":52,"alternative-id":["S2589537026004645"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104211","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumour-agnostic immunotherapy: aligning biological rationale, biomarker precision, and real-world implementation","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104211","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104211"}}